

Second Opinion: Integrating Novel Approaches into the Management of Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What was the approximate complete response rate observed for patients who received TAR-200 monotherapy in the Phase II SunRISe-1 trial for high-risk, BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC)?**
 - a. 20%
 - b. 45%
 - c. 80%**
- 2. Which of the following is the best description of TAR-210?**
 - a. Intravesical gemcitabine/docetaxel
 - b. Intravesical erdafitinib**
 - c. Intravesical avelumab
 - d. Systemic mitomycin C
- 3. A retrospective analysis of circulating tumor DNA (ctDNA) in the Phase III IMvigor010 study evaluating adjuvant atezolizumab versus observation for muscle-invasive bladder cancer revealed which of the following outcomes?**
 - a. Significantly improved disease-free survival (DFS) and overall survival (OS) among patients with negative ctDNA test results who received adjuvant atezolizumab
 - b. Significantly improved DFS and OS among patients with positive ctDNA test results who received adjuvant atezolizumab**
 - c. Significantly improved DFS and OS among patients who received adjuvant atezolizumab, regardless of ctDNA status
- 4. Which of the following statements is true about the relationship between ctDNA status and efficacy outcomes with adjuvant atezolizumab compared to observation for patients with muscle-invasive urothelial carcinoma in the Phase III IMvigor011 trial?**
 - a. Adjuvant atezolizumab was associated with an OS benefit among patients with detectable ctDNA
 - b. A greater reduction in ctDNA levels with adjuvant atezolizumab was associated with longer OS
 - c. Both a and b**
 - d. Neither a nor b
- 5. Which of the following therapies is being compared to intravesical chemotherapy for patients with intermediate-risk NMIBC with susceptible FGFR alterations in the Phase III MoonRISe-1 study?**
 - a. Pemigatinib
 - b. TAR-200
 - c. TAR-200 + cetrelimab
 - d. TAR-210**
 - e. Lirafugratinib (RLY-4008)